CNSX:CGN

Stock Analysis Report

Cognetivity Neurosciences

Executive Summary

Cognetivity Neurosciences Ltd. operates as a healthcare company.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Cognetivity Neurosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.4%

CGN

2.3%

CA Medical Equipment

0.2%

CA Market


1 Year Return

-62.3%

CGN

-11.7%

CA Medical Equipment

3.5%

CA Market

Return vs Industry: CGN underperformed the Canadian Medical Equipment industry which returned -11.7% over the past year.

Return vs Market: CGN underperformed the Canadian Market which returned 3.5% over the past year.


Shareholder returns

CGNIndustryMarket
7 Day7.4%2.3%0.2%
30 Day3.6%-18.1%-3.3%
90 Day-50.0%-19.3%-1.9%
1 Year-62.3%-62.3%-11.7%-11.7%7.3%3.5%
3 Yearn/a-51.5%-51.5%14.7%4.4%
5 Yearn/a-9.6%-9.6%26.2%7.7%

Price Volatility Vs. Market

How volatile is Cognetivity Neurosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cognetivity Neurosciences undervalued compared to its fair value and its price relative to the market?

41.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CGN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CGN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CGN is overvalued based on its PB Ratio (41.8x) compared to the CA Medical Equipment industry average (4.7x).


Next Steps

Future Growth

How is Cognetivity Neurosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

59.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cognetivity Neurosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Cognetivity Neurosciences's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Cognetivity Neurosciences competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Cognetivity Neurosciences performed over the past 5 years?

-53.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CGN is unprofitable, and losses have increased over the past 5 years at a rate of -53.3% per year.

Accelerating Growth: Unable to compare CGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (27.4%).


Return on Equity

High ROE: CGN has a negative Return on Equity (-2156.15%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CGN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CGN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Cognetivity Neurosciences's financial position?


Financial Position Analysis

Short Term Liabilities: CGN's short term assets (CA$303.9K) exceeds its short term liabilities (CA$171.8K)

Long Term Liabilities: CGN has no long term liabilities


Debt to Equity History and Analysis

Debt Level: CGN is debt free.

Reducing Debt: CGN had no debt 5 years ago.


Balance Sheet

Inventory Level: CGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CGN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -68.3% each year


Next Steps

Dividend

What is Cognetivity Neurosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.9%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Cognetivity Neurosciences's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average board tenure


CEO

Sina Habibi 0

0yrs

Tenure

0

Dr. Sina Habibi serves as Co-Founder & Chief Executive Officer at Cognetivity Neurosciences Ltd and also serves as its Director since December 21, 2017. 


Board Age and Tenure

1.8yrs

Average Tenure

53yo

Average Age

Experienced Board: CGN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Denise Lok (35yo)

    CFO & Corporate Secretary

    • Tenure: 0yrs
  • Tom Sawyer (49yo)

    Chief Operating Officer

    • Tenure: 0yrs
  • Sina Habibi

    Co-Founder

    • Tenure: 0yrs
  • Chris Kalafatis

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
  • Mark Phillips

    Chief Compliance Officer & Director

    • Tenure: 1.8yrs
  • Seyed-Mahdi Khaligh-Razavi

    Co-Founder & Chief Scientific Officer

    • Tenure: 0yrs

Board Members

  • Hanspeter Spek (70yo)

    Member of Advisory Board

    • Tenure: 1.3yrs
  • David Velisek (47yo)

    Independent Director

    • Tenure: 3.8yrs
  • Robert, Rob Kang (53yo)

    Independent Director

    • Tenure: 1.8yrs
  • Sina Habibi

    Co-Founder

    • Tenure: 0yrs
  • Chris Kalafatis

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
  • Mark Phillips

    Chief Compliance Officer & Director

    • Tenure: 1.8yrs

Company Information

Cognetivity Neurosciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cognetivity Neurosciences Ltd.
  • Ticker: CGN
  • Exchange: CNSX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$6.672m
  • Shares outstanding: 46.01m
  • Website: https://www.cognetivity.com

Number of Employees


Location

  • Cognetivity Neurosciences Ltd.
  • 1075 West Georgia Street
  • Suite 1980
  • Vancouver
  • British Columbia
  • V6E 3C9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGNCNSX (Canadian National Stock Exchange)YesNew Common SharesCACADMar 2018
1UBDB (Deutsche Boerse AG)YesNew Common SharesDEEURMar 2018
CGNS.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDMar 2018

Biography

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artifici ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 00:35
End of Day Share Price2019/10/22 00:00
Earnings2019/07/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.